3Beutner KR,Spruance SL,Hougham A J,et al.Treatment of genital warts with an immune-response modifier (imiquimod).J Am Acad Dermatol,1998,38:230-239.
4Moore RA,Edwards JE,Hopwood J,et al.Imiquimod for the treatment of genital warts:a quantitative systematic review.BMC Infect Dis,2001,1:3.
5.新药(西药)临床及临床前研究指导原则 [S].[S].卫生部药政局,1993.204-208.
6Sauder DN. Immunomodulatory and pharmacologic properties of imi quimod. J Am Acad Dermatol, 2000, 43( 1 Pt 2) :S6 - 11.
7Buates S, Matlashewski G. Identification of genes induced by a macrophage activator, S - 28463, using gene expression array analysis. Antimicrob Agents Chemother, 2001,45 (4): 1137 - 1142.
8Bums RP Jr, Ferbel B, Tomai M ,et al. The imidazoquinolines, imiquimod and R -848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol, 2000, 94(1):13-23.
9Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R 848 and imiquimod. Cell Immunol, 1999, 191 ( 1 ) :10 - 19.
10Bishop GA, Ramirez LM, Baccam M, et al. The immune response modifier resiquimod mimics CD40 - induced B cell activation. Cell Immunol, 2001, 208( 1 ) :9 - 17.
